Segment Reporting (Tables)

9 Months Ended

Sep. 30, 2025

Segment Reporting [Abstract]

Significant Segment Expenses

Significant segment expenses, as provided to the CODM are as follows:

		Three Months Ended September 30,				Nine Months Ended September 30,
		2025		2024			2025		2024
Sales	$	729,394		554,908			1,479,926		1,047,532
Cost of sales (excluding depreciation expense)		293,838		190,839			569,275		352,496
Research and development expense		269,036		716,979			1,317,416		1,797,759
Other research and development expense 1		1,112,986		1,586,262			4,447,507		4,252,088
Total research and development expense		1,382,022		2,303,241			5,764,923		6,049,847
Sales and marketing expense		1,143,805		1,572,189			3,037,349		2,847,866
General and administrative expense		1,477,800		1,530,791			4,817,485		4,645,412
Depreciation and amortization expense		85,697		76,288			256,835		215,144
Total operating expenses		4,089,324		5,482,509			13,876,592		13,758,269
Total other expense, net		(541,053	)	(289,262	)		(1,715,829	)	(630,303	)
Loss before income taxes		(4,194,821	)	(5,407,702	)		(14,681,770	)	(13,693,536	)
Income tax benefit		—		1,158			(4,188	)	(592	)
Net loss	$	(4,194,821	)	(5,408,860	)		(14,677,582	)	(13,692,944	)

¹ Other research and development expense include clinical affairs, regulatory, manufacturing and quality assurance expenses.